Neutralizing HIV function

November 3, 2011

(Medical Xpress) -- Northeastern researchers have played a key role in studying how antibodies that neutralize HIV function are structured, a further step in ongoing global efforts by scientists to develop a vaccine for the pandemic virus that causes AIDS.

Working under the leadership of Ellis Reinherz of Dana-Farber Cancer Institute, Northeastern’s John R. Engen, a professor of chemistry and chemical biology in the College of Science, used mass spectrometry to analyze the 2F5 antibody, one of several broadly neutralizing anti-HIV that prevent the development of

Broadly neutralizing antibodies are extremely rare when found naturally. In many cases, antibodies raised in the lab may interact but are unable to neutralize. 

The researchers, whose results were published this month in the journal Nature Structural & Molecular Biology, probed this problem. 

“The recognition by this antibody is complicated,” said Engen, describing his work to analyze the 2F5 antibody interaction with the protein gp41. “2F5 binds to a portion of gp41, a specific protein in the HIV outer lipid wall, then 2F5 physically moves. That movement is quite important for the final recognition process and to create an artificial antibody that does that movement will be quite tricky.”

The paper examines the structure and operation of antibodies that would play an essential role in an eventual HIV or AIDS vaccine. The research was financed and supervised by the Dana-Farber Cancer Institute, the National Institutes of Health and the Collaboration for AIDS Vaccine Discovery, which is funded by the Bill and Melinda Gates Foundation.

Engen said the work included some of the most difficult and rewarding projects he has been involved in in recent years.

“My lab at Northeastern has been doing this mass spectrometry method to look at protein conformation for a long time, and this is one of the more exciting projects because it has to do with looking at diseases and how they work,” Engen said.

Engen said Northeastern’s role was part of a larger interdisciplinary team’s efforts, and it was an important contribution that is uniquely suited to Northeastern, given the well established bioanalytical expertise within the Barnett Institute of Chemical and Biological Analysis and the Department of Chemistry and Chemical Biology.  

“We’re really excited to work on collaborative projects like this in which different expertise is brought to bear on a single problem of high importance,” Engen said.

Explore further: Scientists Find Rare, Potent Antibody to HIV-1

More information: www.nature.com/nsmb/journal/vaop/ncurrent/full/nsmb.2154.html

Related Stories

Scientists Find Rare, Potent Antibody to HIV-1

February 23, 2009

(PhysOrg.com) -- Scientists at Duke University Medical Center have for the first time isolated an important antibody in human serum that could potentially play a key role in the design of an AIDS vaccine. The research appears ...

The future of drug development

September 3, 2010

John Engen, associate professor of chemistry and chemical biology at the Northeastern University, is at the forefront of research that will advance drug discovery and development by making it easier to analyze certain kinds ...

Why so many antibodies fail to protect against HIV infection

November 18, 2010

Researchers have been stymied for years over the fact that people infected with the AIDS virus do indeed produce antibodies in response to the pathogen – antibodies that turn out to be ineffective in blocking infection.

Breast milk antibody fights HIV but needs boost

September 19, 2011

Breast milk antibody both neutralizes human immunodeficiency virus (HIV) and kills HIV-infected cells, according to a paper in the September 2011 issue of the Journal of Virology.

Recommended for you

Mutational tug of war over HIV's disease-inducing potential

August 23, 2016

A study from Emory AIDS researchers shows how the expected disease severity when someone is newly infected by HIV reflects a balance between the virus' invisibility to the host's immune system and its ability to reproduce.

Dormant copies of HIV mostly defective, new study shows

August 8, 2016

After fully sequencing the latent HIV "provirus" genomes from 19 people being treated for HIV, scientists at Johns Hopkins Medicine report that even in patients who start treatment very early, the only widely available method ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.